A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 for Injection in Subjects With Advanced Solid Tumors

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.1 site in 1 country180 target enrollmentDecember 13, 2024

ConditionsAdvanced Solid Tumors

InterventionsSKB500

DrugsSKB500

Overview

Phase: Phase 1
Intervention: SKB500
Conditions: Advanced Solid Tumors
Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Enrollment: 180
Locations: 1
Primary Endpoint: Evaluate the incidence of adverse events (AEs)
Status: Recruiting
Last Updated: 4 months ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This study aims to evaluate the safety, tolerability, PK profile, immunogenicity, and antitumor activity of SKB500 in subjects with advanced solid tumors.

Detailed Description

This study is a multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, PK profile, immunogenicity, and antitumor activity of SKB500 in subjects with advanced solid tumors. The study includes a dose-escalation phase, a dose-expansion phase, and an indication-expansion phase.

Registry

clinicaltrials.gov

Start Date

December 13, 2024

End Date

December 31, 2028

Last Updated

4 months ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Male or female participants between 18 and 75 years old.
•Histologically or cytologically confirmed advanced solid tumors for which standard treatment either does not exist or has proven ineffective or intolerable.
•Subjects should ideally provide a tumor tissue sample for biomarker testing during the screening period.
•Has at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
•ECOG performance status score of 0 or
•Expected survival of at least 12 weeks.
•Has adequate hematopoietic, renal and hepatic functions.
•Have recovered to grade ≤ 1 of prior anti-cancer treatment toxicities.
•Male and female subjects must agree to use highly effective contraceptive methods throughout the study.
•Subjects must voluntarily enter the study, sign the informed consent form, and be able to comply with the visits and procedures.

Exclusion Criteria

•Subjects with known active CNS metastases, carcinomatous meningitis, leptomeningeal metastases, or spinal cord compression.
•Subjects with other malignancies within 5 years before the first dose.
•Any severe and/or uncontrolled concurrent disease that may interfere with the subject's participation in the study.
•Active hepatitis B, or hepatitis C; active tuberculosis, or human immunodeficiency virus (HIV) test positive, or known acquired immunodeficiency syndrome (AIDS).
•History of allergy to any component of SKB500 or history of severe hypersensitivity reactions to other monoclonal antibodies.
•Subjects with a history of interstitial lung disease, non-infectious pneumonia, or other pulmonary diseases significantly affecting lung function.
•History of allogeneic organ transplantation or hematopoietic stem cell transplantation.
•Uncontrolled pleural effusion, ascites, or pericardial effusion.
•Have received ADCs with the same target or the same toxins.
•Have received chemotherapy, small molecule targeted therapy, and traditional Chinese medicine preparations within 14 days or 5 half-lives before the first dose; have received any immunotherapy, large molecule anticancer drug treatment, or more than 30% bone marrow radiation or extensive radiotherapy within 28 days before the first dose.